Emerging research indicates that GLP-1 medications, originally developed for diabetes and obesity, may be effective in treating substance use disorders. Two recent studies involving hundreds of thousands of patients found that individuals taking these drugs had a lower risk of hospitalization for alcohol use disorder and a decreased likelihood of developing substance use issues generally. Researchers suggest the medications may function by targeting the craving center of the brain.
While GLP-1 drugs have been available since 2005, their impact on addiction has gained attention as their use has expanded. Approximately 15% of Americans report having used a GLP-1 medication, which includes brand names such as Ozempic, Mounjaro, Wegovy, and Zepbound. Medical professionals noted that patients prescribed these drugs for weight or blood sugar management often reported a spontaneous reduction or cessation of alcohol consumption.
Specific data from a Swedish study of 200,000 people showed a correlation between GLP-1 use and reduced hospitalizations for alcohol-related issues. Additionally, a study of 600,000 veterans with type 2 diabetes by Washington University School of Medicine found the drugs were associated with a lower risk of developing various substance use disorders. Dr. Ziyad Al-Aly, the senior author of the veteran study, noted that unlike traditional treatments that target one substance, these medications appeared to work across different addictive substances.
If the Food and Drug Administration (FDA) eventually approves GLP-1s for this purpose, patients would notice a concrete change in their healthcare options and potentially their insurance coverage for addiction treatment. Currently, treating addiction is not an FDA-approved use for these drugs, meaning patients may not have legal or financial access to them for that specific purpose. The shift would represent a change in how medical professionals approach the "craving center" of the brain, potentially altering the day-to-day management of chronic addictive behaviors.
The knock-on effects could influence the pharmaceutical market and future public health policy regarding addiction recovery programs. While the alcohol-related findings are more established, research into cocaine, methamphetamine, and opioid addiction remains inconclusive. What happens next depends on further research and clinical trials; the medical community cannot yet say with certainty when or if these drugs will become a standard tool for addiction treatment. No specific dates for FDA reviews or new study completions were reported.